Trial Profile
A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to Alzheimer´s Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Iclepertin (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183969).
- 31 Jul 2020 Results assessing efficacy and safety of the BI 425809, in mild to moderate Alzheimers dementia (AD), presented at the Alzheimer's Association International Conference 2020
- 24 Oct 2019 Status changed from active, no longer recruiting to completed.